clipped from www.businesswire.com

Rheumatoid Arthritis Market Expected to More than Double in Value to US$27 Billion by 2015

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c87503) has announced the addition of "Rheumatoid Arthritis Drug Discoveries: What The Future Holds" to their offering.

With significant unmet clinical need and the progressive introduction of higher value and effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to US$27 billion by 2015. This new management report provides a complete examination of the RA market and its prospects in the medium term.

Rheumatoid arthritis is the most common chronic inflammatory joint disease. The incidence of RA among white populations is approximately 3 people per 10,000 or 0.03 per cent per annum worldwide,

The commonest age of onset is between 40 and 50 years of age.

A rising market

The rheumatoid arthritis sector is set for substantial growth.

clipped from www.lookinggood-feelinggreat.co.uk

 Painful joints 'not just an effect of ageing'

Often wrongly believed to be just part of the ageing process, painful joints, associated with arthritis, can affect anyone at any time in their lives, according to NHS Direct.

Trisha Hamilton, deputy chief nurse at NHS Direct, explained: "It is recognised that rheumatoid arthritis affects all age groups. Rheumatoid arthritis is an inflammatory process that happens when the body's immune system is attacking and destroying its own joint."